

PHARMACEUTICAL 2019

NightHawk Biosciences Inc. Rank 118 of 363









PHARMACEUTICAL 2019



NightHawk Biosciences Inc. Rank 118 of 363

The relative strengths and weaknesses of NightHawk Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NightHawk Biosciences Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 29% points. The greatest weakness of NightHawk Biosciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 159%, being 122% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	28,714
Cost of Goods Sold	0
Intangible Assets	2,189
Liabilities, Current	4,872
Liabilities, Non-Current	214
Other Assets	6,217
Other Compr. Net Income	1,004
Other Expenses	-490
Other Liabilities	2,435
Other Net Income	384
Other Revenues	5,794
Property and Equipment	643
Research and Development	16,233
Selling, General and Administrative Expense	7,025

Output Variable	Value in 1000 USD
Assets	37,764
Liabilities	7,521
Expenses	22,769
Revenues	5,794
Stockholders Equity	30,243
Net Income	-16,591
Comprehensive Net Income	-16,090
Economic Capital Ratio	159%

